CLAIMS

1. Use of an isolated polypeptide or a nucleic acid encoding the isolated polypeptide, comprising a modified sequence, wherein the modified sequence is at least 95% identical to SEQ ID NO: 1 and has a F to A mutation or a conservative substitution thereof at a position corresponding to F32 of SEQ ID NO: 1, in the manufacture of a medicament for treating a T cell-mediated autoimmune disease or increasing a level of regulatory T (T_{reg}) cells in an inflammatory disease.

2. The use of claim 1, wherein the IgG region in the first isolated polypeptide is sialylated at a level higher than that of IgG in the subject.

3. The use of any one of claims 1-2, wherein the subject has an inflammatory disease.

4. The use of claim 3, wherein the inflammatory disease is an autoimmune disease.

5. The use of claim 4, wherein the autoimmune disease is a T cell-mediated autoimmune disease.

6. The use of claim 5, wherein the T cell-mediated autoimmune disease is selected from the group consisting of multiple sclerosis and type I diabetes.

7. The use of any one of claims 1-6, wherein the isolated polypeptide has an ability to bind to DC-SIGN, hFcγRIIA, or hFcγRIIB.

8. The use of claim 7, wherein the isolated polypeptide has an ability to bind to hFcγRIIA or hFcγRIIB at a K_D of $2x10^{-5}$ M or lower (i.e., K_A of 5.0×10^4 M^{-1} or higher).

9. The use of any one of claims 1-8, wherein the modified sequence is (a) substantially free of sialylation or (b) sialylated at a level lower than that of IgG of the subject.

10. The use of any one of claims 1-9, wherein the modified sequence is at least 95% identical to SEQ ID NO: 2.